MCID: DRG002
MIFTS: 43

Drug-Induced Hepatitis

Categories: Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Drug-Induced Hepatitis

MalaCards integrated aliases for Drug-Induced Hepatitis:

Name: Drug-Induced Hepatitis 12 15 17
Chemical and Drug Induced Liver Injury, Chronic 43
Hepatitis, Chronic, Drug-Induced 71
Drug-Induced Chronic Hepatitis 12
Hepatitis, Drug-Induced 71

Classifications:



External Ids:

Disease Ontology 12 DOID:2044
MeSH 43 D056487
SNOMED-CT 67 235889003
UMLS 71 C0524912 C1262760

Summaries for Drug-Induced Hepatitis

MalaCards based summary : Drug-Induced Hepatitis, also known as chemical and drug induced liver injury, chronic, is related to pulmonary tuberculosis and peptic ulcer disease. An important gene associated with Drug-Induced Hepatitis is NAT2 (N-Acetyltransferase 2), and among its related pathways/superpathways are Metabolism and Cytochrome P450 - arranged by substrate type. The drugs Acetylcysteine and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include Liver, testes and t cells, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 74 Hepatotoxicity (from hepatic toxicity) implies chemical-driven liver damage. Drug-induced liver injury... more...

Related Diseases for Drug-Induced Hepatitis

Diseases related to Drug-Induced Hepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 258)
# Related Disease Score Top Affiliating Genes
1 pulmonary tuberculosis 30.6 TNF NAT2 ALB
2 peptic ulcer disease 30.1 TNF CYP2C19 ALB
3 acute liver failure 30.0 GPT F2 ALB
4 cholestasis 29.9 TNF GPT F2 ALB
5 alcohol use disorder 29.7 GPT CYP2E1 CYP2C19 ALB
6 fatty liver disease 29.7 TNF GPT CYP2E1 ALB
7 constipation 29.6 TNF GPT CYP2D6 ALB
8 exanthem 29.6 TNF GPT F2 ALB
9 hepatitis 29.5 TNF STAT3 SEPSECS GPT F2
10 neutropenia 29.5 UGT1A1 TNF GPT ALB
11 gilbert syndrome 29.5 UGT1A3 UGT1A1 GPT ALB
12 acute kidney failure 29.4 GPT F2 ALB
13 abdominal tuberculosis 29.4 TNF GPT F2 ALB
14 obstructive jaundice 29.3 TNF GPT F2 ALB
15 intracranial hypertension 29.3 TNF F2 ALB
16 alcoholic hepatitis 29.2 TNF GPT F2 CYP2E1 ALB
17 hepatitis a 29.2 TNF SEPSECS GPT F2 ALB
18 cholangitis 29.1 TNF GPT F2 ALB
19 hepatitis d 29.1 IFNL3 GPT F2 CYP2D6 CYP2C9
20 hepatitis b 28.9 TNF STAT3 GPT F2 ALB
21 bilirubin metabolic disorder 28.8 UGT1A3 UGT1A1 GPT F2 ALB
22 viral hepatitis 28.7 TNF SEPSECS IFNL3 GPT F2 ALB
23 primary biliary cirrhosis 28.7 TNF SEPSECS GPT F2 ALB
24 vascular disease 28.7 TNF F2 CYP2C9 CYP2C19 ALB
25 portal hypertension 28.7 TNF IFNL3 GPT F2 ALB
26 liver cirrhosis 28.7 GPT F2 CYP2E1 CYP1A2 ALB
27 liver disease 28.4 UGT1A1 TNF SEPSECS GPT F2 CYP2E1
28 thrombocytopenia 28.4 TNF STAT3 GPT F2 ALB
29 autoimmune hepatitis 28.0 TNF SEPSECS GPT F2 CYP2D6 CYP1A2
30 hepatocellular carcinoma 26.6 TNF STAT3 IFNL3 GSTM1 GPT F2
31 hearing loss, noise-induced 10.5 GSTT1 GSTM1
32 colorectal cancer 8 10.5 GSTT1 GSTM1
33 1,4-phenylenediamine allergic contact dermatitis 10.5 TNF NAT2
34 dipetalonemiasis 10.4 GPT ALB
35 koro 10.4 CYP2C9 ALB
36 heterophyiasis 10.4 GPT ALB
37 isolated cleft lip 10.4 GSTT1 GSTM1
38 sister chromatid exchange, frequency of 10.4 GSTT1 GSTM1 CYP2E1
39 mutagen sensitivity 10.4 NAT2 GSTT1 GSTM1
40 critical illness polyneuropathy 10.4 GPT ALB
41 toxic oil syndrome 10.4 NAT2 GSTM1 CYP2D6
42 cardia cancer 10.3 GSTT1 GSTM1 CYP2E1
43 abacavir allergy 10.3 IFNL3 CYP2C9
44 jejunoileitis 10.3 TNF ALB
45 senile cataract 10.3 GSTT1 GSTM1 ALB
46 gastrointestinal tuberculosis 10.3 TNF ALB
47 intestinal tuberculosis 10.3 TNF ALB
48 angiodysplasia of intestine 10.3 CYP2C9 CYP1A2
49 granulomatous hepatitis 10.2 TNF GPT ALB
50 heart aneurysm 10.2 TNF GPT ALB

Graphical network of the top 20 diseases related to Drug-Induced Hepatitis:



Diseases related to Drug-Induced Hepatitis

Symptoms & Phenotypes for Drug-Induced Hepatitis

GenomeRNAi Phenotypes related to Drug-Induced Hepatitis according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-10 9.58 CYP1A2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-123 9.58 CYP1A2
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-127 9.58 CYP2D6 STAT3
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.58 CYP1A2
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.58 CYP2D6
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-147 9.58 UGT1A3
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-167 9.58 STAT3
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.58 CYP2D6
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 9.58 CYP2D6
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-184 9.58 CYP2D6
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-187 9.58 STAT3
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.58 UGT1A3
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-211 9.58 UGT1A3
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-212 9.58 CYP2D6
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-26 9.58 CYP2D6
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.58 STAT3
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-82 9.58 CYP1A2

Drugs & Therapeutics for Drug-Induced Hepatitis

Drugs for Drug-Induced Hepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
2 Liver Extracts Phase 2, Phase 3
3 Protective Agents Phase 2, Phase 3
4 Respiratory System Agents Phase 2, Phase 3
5 Anti-Infective Agents Phase 2, Phase 3
6 Antidotes Phase 2, Phase 3
7 Antioxidants Phase 2, Phase 3
8 Antiviral Agents Phase 2, Phase 3
9 Expectorants Phase 2, Phase 3
10 N-monoacetylcystine Phase 2, Phase 3
11
Phenylacetic acid Approved Phase 2 103-82-2 999
12
Acetaminophen Approved Phase 2 103-90-2 1983
13
Prednisolone phosphate Approved, Vet_approved Phase 1, Phase 2 302-25-0
14
Alprostadil Approved, Investigational Phase 1, Phase 2 745-65-3 149351 5280723
15
Methylprednisolone Approved, Vet_approved Phase 1, Phase 2 83-43-2 6741
16
Methylprednisolone hemisuccinate Approved Phase 1, Phase 2 2921-57-5
17
Ursodeoxycholic acid Approved, Investigational Phase 1, Phase 2 128-13-2 31401
18
Prednisolone Approved, Vet_approved Phase 1, Phase 2 50-24-8 5755
19 Prednisolone acetate Approved, Vet_approved Phase 1, Phase 2 52-21-1
20
glycyrrhizin Approved, Experimental Phase 1, Phase 2 1405-86-3 3495
21
Ornithine Approved, Nutraceutical Phase 2 70-26-8, 3184-13-2 6262
22
Prednisolone hemisuccinate Experimental Phase 1, Phase 2 2920-86-7
23 Antimetabolites Phase 2
24 Hormones Phase 1, Phase 2
25 Antineoplastic Agents, Hormonal Phase 1, Phase 2
26 Methylprednisolone Acetate Phase 1, Phase 2
27 Antiemetics Phase 1, Phase 2
28 Neuroprotective Agents Phase 1, Phase 2
29 Hormone Antagonists Phase 1, Phase 2
30 glucocorticoids Phase 1, Phase 2
31 Gastrointestinal Agents Phase 1, Phase 2
32 Anti-Inflammatory Agents Phase 1, Phase 2
33
Rifampicin Approved 13292-46-1 5381226 5458213
34
Pyrazinamide Approved, Investigational 98-96-4 1046
35
Isoniazid Approved, Investigational 54-85-3 3767
36
Pomegranate Experimental, Investigational
37 interferons
38 Antitubercular Agents
39 Immunoglobulins
40 Antibodies
41 Hepatitis C Antibodies
42 Anti-Retroviral Agents
43 HIV Antibodies

Interventional clinical trials:

(show all 11)
# Name Status NCT ID Phase Drugs
1 A Randomised Controlled Trial of Intravenous N-acetylcysteine in the Management of Antituberculous Drug-induced Hepatitis Completed NCT02182167 Phase 2, Phase 3 IV N-acetylcysteine (NAC);Water
2 A Randomized Controlled Clinical Trial on the Efficacy and Safety of Glucocorticosteroid in the Patients With Chronic Recurrent Drug-induced Liver Injury Unknown status NCT02651350 Phase 1, Phase 2 Methylprednisolone;Standard Treatment
3 A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure/Severe Acute Liver Injury Completed NCT01548690 Phase 2 Ornithine Phenylacetate
4 The Efficacy and Safety of 36 Weeks Short-Term Optimization Treatment of Glucocorticosteroid in the Patients With Chronic Recurrent Drug-Induced Liver Injury Recruiting NCT03266146 Phase 1, Phase 2 36 Weeks Methylprednisolone;48 weeks Methylprednisolone
5 Adverse Drug Reactions to Antituberculosis Drugs in the Treatment of Latent Tuberculosis Infection in Korean Health Care Workers Unknown status NCT03312647
6 A Retrospective Epidemiologic Study on Incidence and Treatment Status of Hospitalized Drug Induced Liver Injury Patients in Mainland China Completed NCT02407964
7 Prospective Study of N-acetyltransferase2 (NAT2) Gene and Rifampicin Induced Cytochrome P-450 as Susceptible Risk Factors for Antituberculosis Drug Induced Hepatitis Completed NCT00834353 ATT
8 Measurement of Drug Levels and Their Correlation With Hepatotoxicity During Antituberculosis Treatment Completed NCT00929786
9 Genetic Polymorphisms of ABCB11 and ABCB4 in Women With Intrahepatic Cholestasis of Pregnancy (ICP) and in Their First Degree Relatives Recruiting NCT04281082 ursofalk
10 Incidence and Mortality of Hepatocellular Carcinoma in HIV-infected Individuals in an Asian Population Recruiting NCT03702998
11 The Beneficial Effects of Pomegranate on Hearing of Patients Without Hemodialysis: A Prospective, Randomized, Double-blinded Clinical Trial Recruiting NCT03575390

Search NIH Clinical Center for Drug-Induced Hepatitis

Cochrane evidence based reviews: chemical and drug induced liver injury, chronic

Genetic Tests for Drug-Induced Hepatitis

Anatomical Context for Drug-Induced Hepatitis

MalaCards organs/tissues related to Drug-Induced Hepatitis:

40
Liver, Testes, T Cells, Heart, Kidney, Brain, Breast
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Drug-Induced Hepatitis:
# Tissue Anatomical CompartmentCell Relevance
1 Liver Liver Lobule Hepatocytes Affected by disease

Publications for Drug-Induced Hepatitis

Articles related to Drug-Induced Hepatitis:

(show top 50) (show all 540)
# Title Authors PMID Year
1
Oxidative stress and ER stress may contribute to drug-induced hepatitis in tuberculous meningitis. 61
32304905 2020
2
NRF2 activates growth factor genes and downstream AKT signaling to induce mouse and human hepatomegaly. 61
32105670 2020
3
Liver Abnormalities in Patients with Psoriatic Arthritis. 61
31615918 2020
4
Initial dosage optimization of tacrolimus in Chinese pediatric patients undergoing kidney transplantation based on population pharmacokinetics and pharmacogenetics. 61
32452705 2020
5
Genomic characterization of XDR Klebsiella pneumoniae ST147 co-resistant to carbapenem and colistin - The first report in India. 61
32470551 2020
6
Changes in Real-world Practice Patterns of Antiepileptic Drugs for Status Epilepticus: A Nationwide Observational Study in Japan. 61
32009125 2020
7
Spontaneous extradural hematoma: a rare entity. 61
29179597 2020
8
Tuberculosis: A Cunning Disease Presenting with Endopericarditis-Associated Bilateral Uveitis 61
31893593 2019
9
Drug induced hepatitis mimicking Wilson's disease secondary to the use of complex naturopathic regimens: a case report. 61
31775657 2019
10
From tinnitus to acute hepatitis: Drug-induced injury caused by use of naftidrofuryl for one year. 61
31023552 2019
11
TLR4 promotes liver inflammation by activating the JNK pathway. 61
31539158 2019
12
Antifungals in a case of basidiobolomycosis: role and limitations. 61
31570348 2019
13
Wilson Disease Presenting With Acute on Chronic Liver Failure: A Single-Center Experience of Outcome and Predictors of Mortality in 68 Patients. 61
31695246 2019
14
In drug-induced, immune-mediated hepatitis, interleukin-33 reduces hepatitis and improves survival independently and as a consequence of FoxP3+ T-cell activity. 61
30030493 2019
15
Wuzhi capsule and haemoglobin influence tacrolimus elimination in paediatric kidney transplantation patients in a population pharmacokinetics analysis: A retrospective study. 61
30864229 2019
16
Impact of renal function-based anti-tuberculosis drug dosage adjustment on efficacy and safety outcomes in pulmonary tuberculosis complicated with chronic kidney disease. 61
31046706 2019
17
Аdеmethionine in the treatment of fatigue in liver diseases: a systematic review. 61
31094184 2019
18
[Mitoxantrone-cytarabine-etoposide induction therapy in children with acute myeloid leukemia: a single-center study of complications and clinical outcomes]. 61
30675859 2019
19
Outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in HIV-infected patients when using systemic steroids and/or intravenous immunoglobulins in Pietermaritzburg, South Africa. 61
31308970 2019
20
Six versus 12 Months of Anti Tubercular Therapy in Patients With Biopsy Proven Spinal Tuberculosis: A Single Center, Open Labeled, Prospective Randomized Clinical Trial-A Pilot study. 61
30045346 2019
21
Study of glutathione S-transferase levels in patients receiving intravenous paracetamol perioperatively: A randomized controlled trial. 61
30421393 2018
22
CD31 induces inflammatory response by promoting hepatic inflammatory response and cell apoptosis. 61
30468504 2018
23
Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. 61
30080294 2018
24
Identification of a Shared Cytochrome p4502E1 Epitope Found in Anesthetic Drug-Induced and Viral Hepatitis. 61
30305319 2018
25
Acute Liver Failure. 61
30485882 2018
26
Evaluation of Adverse Reactions Induced by Anti-Tuberculosis Drugs in Hospital Pulau Pinang. 61
30914867 2018
27
Mortality data from the European Adrenal Insufficiency Registry-Patient characterization and associations. 61
29682773 2018
28
Gastrointestinal beriberi: a forme fruste of Wernicke's encephalopathy? 61
29982183 2018
29
Liver maximum capacity (LiMAx) test as a helpful prognostic tool in acute liver failure with sepsis: a case report. 61
29925334 2018
30
[Changing trends in etiologies of hospitalized patients with liver disease during 2006 -2014]. 61
30317759 2018
31
Two-step progression of varenicline-induced autoimmune hepatitis. 61
29383494 2018
32
Liver Disease During Pregnancy: A Challenging Clinical Issue. 61
29905165 2018
33
Prevalence of antinuclear antibodies in hidradenitis suppurativa. 61
29878616 2018
34
Hepatobiliary diseases in people with HIV infection at the Lome, Togo, University Hospital: epidemiologic and diagnostic aspects. 61
29997079 2018
35
Lansoprazole prevents the progression of liver fibrosis in non-alcoholic steatohepatitis model rats. 61
29355950 2018
36
Acute Liver Failure Induced by Carthamus tinctorius Oil: Case Reports and Literature Review. 61
29579831 2018
37
A 19-Year Retrospective Study of Adverse Drug Reactions to Multidrug Therapy in Leprosy Requiring a Change in Regime. 61
29441295 2018
38
Disseminated toxoplasmosis in a patient with advanced acquired immunodeficiency syndrome. 61
29588907 2018
39
Is drug-induced hepatitis related to the severity of tuberculous meningitis? 61
29438557 2017
40
Management of chronic vulvovaginal candidiasis: a long term retrospective study. 61
27250078 2017
41
Letrozole-induced hepatitis with autoimmune features: a rare adverse drug reaction with review of the relevant literature. 61
29230302 2017
42
Risk factors for readmission to hospital in patients with tuberculosis in Tehran, Iran: three-year surveillance. 61
28166697 2017
43
Letter: autoimmune hepatitis-drug-induced liver injury must always be excluded. Authors' reply. 61
28677278 2017
44
Letter: autoimmune hepatitis-drug-induced liver injury must always be excluded. 61
28677284 2017
45
[Value of detection of serum glypican-3 level in diagnosis and therapeutic effect evaluation of primary hepatocellular carcinoma]. 61
28801286 2017
46
Psoriasis and the liver: problems, causes and course. 61
26916498 2017
47
18F-FDG PET/CT of Tuberculosis Meningitis and Carotid Pseudoaneurysm. 61
28394836 2017
48
Clinical and radiological spectrum of intracranial tuberculosis: A hospital based study in Northeast India. 61
28410693 2017
49
Recurrent Drug-Induced Hepatitis in Tuberculosis-Comparison of Two Drug Regimens. 61
26057141 2017
50
Baseline HBV load increases the risk of anti-tuberculous drug-induced hepatitis flares in patients with tuberculosis. 61
28224437 2017

Variations for Drug-Induced Hepatitis

Expression for Drug-Induced Hepatitis

Search GEO for disease gene expression data for Drug-Induced Hepatitis.

Pathways for Drug-Induced Hepatitis

Pathways related to Drug-Induced Hepatitis according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 UGT1A3 UGT1A1 SEPSECS NAT2 GSTT1 GSTM1
2
Show member pathways
13.18 UGT1A3 UGT1A1 NAT2 GSTT1 GSTM1 CYP2E1
3
Show member pathways
12.68 UGT1A3 UGT1A1 NAT2 GSTT1 GSTM1 CYP2E1
4 12.43 UGT1A3 UGT1A1 CYP2D6 CYP1A2
5
Show member pathways
11.99 UGT1A3 UGT1A1 GSTM1 CYP2D6 CYP2C9 CYP2C19
6
Show member pathways
11.95 CYP2E1 CYP2C9 CYP2C19 CYP1A2
7
Show member pathways
11.92 UGT1A3 CYP2E1 CYP2D6 CYP2C9 CYP2C19 CYP1A2
8 11.9 CYP2D6 CYP2C9 CYP2C19
9
Show member pathways
11.68 UGT1A3 UGT1A1 CYP2E1 CYP1A2
10
Show member pathways
11.6 UGT1A1 CYP2E1 CYP2D6 CYP2C9 CYP2C19 CYP1A2
11 11.56 F2 CYP2C9 CYP2C19 CYP1A2
12
Show member pathways
11.53 CYP2C9 CYP2C19 CYP1A2
13 11.52 UGT1A3 UGT1A1 TNF CYP1A2
14
Show member pathways
11.5 UGT1A1 CYP2D6 CYP2C9
15
Show member pathways
11.42 STAT3 NAT2 GSTM1
16
Show member pathways
11.4 UGT1A3 UGT1A1 GSTT1 GSTM1 CYP2E1 CYP2D6
17
Show member pathways
11.37 UGT1A1 CYP2D6 CYP2C9 CYP1A2
18 11.34 CYP2D6 CYP2C19 CYP1A2
19
Show member pathways
11.34 UGT1A3 UGT1A1 GSTM1 CYP1A2
20
Show member pathways
11.33 UGT1A1 CYP2D6 CYP2C9 CYP2C19 CYP1A2
21 11.31 CYP2E1 CYP2C9 CYP1A2
22 11.3 UGT1A3 UGT1A1 CYP2C9 CYP2C19
23
Show member pathways
11.22 UGT1A3 CYP2E1 CYP2D6 CYP2C9 CYP2C19 CYP1A2
24 11.15 GSTT1 GSTM1 CYP2E1 CYP2C9 CYP1A2
25
Show member pathways
11.13 NAT2 CYP2E1 CYP1A2
26
Show member pathways
11.04 UGT1A3 UGT1A1 CYP2E1 CYP2D6 CYP2C9 CYP2C19
27
Show member pathways
10.86 CYP2D6 CYP1A2
28 10.83 UGT1A3 CYP2D6
29 10.82 UGT1A1 GSTT1
30 10.78 UGT1A3 CYP2D6
31 10.75 STAT3 CYP1A2
32 10.58 CYP2D6 CYP1A2
33 10.4 GSTM1 CYP2E1

GO Terms for Drug-Induced Hepatitis

Cellular components related to Drug-Induced Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.86 UGT1A3 UGT1A1 CYP2E1 CYP2D6 CYP2C9 CYP2C19
2 endoplasmic reticulum membrane GO:0005789 9.7 UGT1A3 UGT1A1 CYP2E1 CYP2D6 CYP2C9 CYP2C19
3 intracellular membrane-bounded organelle GO:0043231 9.5 UGT1A3 UGT1A1 CYP2E1 CYP2D6 CYP2C9 CYP2C19
4 organelle membrane GO:0031090 9.02 CYP2E1 CYP2D6 CYP2C9 CYP2C19 CYP1A2

Biological processes related to Drug-Induced Hepatitis according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 10 CYP2E1 CYP2D6 CYP2C9 CYP2C19 CYP1A2
2 response to drug GO:0042493 9.92 UGT1A1 STAT3 CYP2E1 CYP1A2
3 fatty acid metabolic process GO:0006631 9.88 CYP2E1 CYP2D6 CYP2C19 CYP1A2
4 steroid metabolic process GO:0008202 9.85 UGT1A1 CYP2E1 CYP2D6 CYP2C9 CYP2C19 CYP1A2
5 response to organic substance GO:0010033 9.84 UGT1A1 TNF STAT3 CYP1A2
6 response to ethanol GO:0045471 9.81 UGT1A1 STAT3 CYP2E1
7 xenobiotic metabolic process GO:0006805 9.8 NAT2 CYP2E1 CYP2D6 CYP2C9 CYP2C19 CYP1A2
8 cholesterol metabolic process GO:0008203 9.79 CYP2D6 CYP2C9 CYP1A2
9 long-chain fatty acid biosynthetic process GO:0042759 9.78 CYP2E1 CYP2D6 CYP2C9 CYP1A2
10 organic acid metabolic process GO:0006082 9.76 CYP2E1 CYP2D6 CYP2C9 CYP2C19
11 acute-phase response GO:0006953 9.75 UGT1A1 STAT3 F2
12 arachidonic acid metabolic process GO:0019369 9.73 CYP2D6 CYP2C9 CYP1A2
13 epoxygenase P450 pathway GO:0019373 9.73 CYP2E1 CYP2C9 CYP2C19 CYP1A2
14 estrogen metabolic process GO:0008210 9.71 UGT1A1 CYP2D6 CYP2C9 CYP1A2
15 oxidative demethylation GO:0070989 9.7 CYP2D6 CYP2C9 CYP1A2
16 omega-hydroxylase P450 pathway GO:0097267 9.69 CYP2C9 CYP2C19 CYP1A2
17 drug catabolic process GO:0042737 9.67 CYP2D6 CYP2C9 CYP1A2
18 exogenous drug catabolic process GO:0042738 9.65 CYP2E1 CYP2D6 CYP2C9 CYP2C19 CYP1A2
19 positive regulation of interleukin-6 biosynthetic process GO:0045410 9.63 TNF STAT3
20 drug metabolic process GO:0017144 9.63 UGT1A1 CYP2E1 CYP2D6 CYP2C9 CYP2C19 CYP1A2
21 cellular glucuronidation GO:0052695 9.62 UGT1A3 UGT1A1
22 xenobiotic glucuronidation GO:0052697 9.6 UGT1A3 UGT1A1
23 flavonoid glucuronidation GO:0052696 9.59 UGT1A3 UGT1A1
24 monocarboxylic acid metabolic process GO:0032787 9.57 CYP2C9 CYP1A2
25 alkaloid metabolic process GO:0009820 9.55 CYP2D6 CYP1A2
26 heterocycle metabolic process GO:0046483 9.35 UGT1A1 CYP2E1 CYP2D6 CYP2C19 CYP1A2
27 monoterpenoid metabolic process GO:0016098 9.02 CYP2E1 CYP2D6 CYP2C9 CYP2C19 CYP1A2

Molecular functions related to Drug-Induced Hepatitis according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.96 CYP2E1 CYP2D6 CYP2C9 CYP2C19 CYP1A2
2 enzyme binding GO:0019899 9.91 UGT1A3 UGT1A1 GSTM1 CYP2E1 CYP2C19 CYP1A2
3 heme binding GO:0020037 9.8 CYP2E1 CYP2D6 CYP2C9 CYP2C19 CYP1A2
4 iron ion binding GO:0005506 9.77 CYP2E1 CYP2D6 CYP2C9 CYP2C19 CYP1A2
5 drug binding GO:0008144 9.72 CYP2D6 CYP2C9 ALB
6 oxygen binding GO:0019825 9.7 CYP2E1 CYP2C19 ALB
7 monooxygenase activity GO:0004497 9.65 CYP2E1 CYP2D6 CYP2C9 CYP2C19 CYP1A2
8 arachidonic acid epoxygenase activity GO:0008392 9.63 CYP2E1 CYP2C9 CYP2C19
9 steroid hydroxylase activity GO:0008395 9.62 CYP2E1 CYP2D6 CYP2C9 CYP2C19
10 caffeine oxidase activity GO:0034875 9.54 CYP2C9 CYP1A2
11 (R)-limonene 6-monooxygenase activity GO:0052741 9.51 CYP2C9 CYP2C19
12 (S)-limonene 7-monooxygenase activity GO:0018676 9.49 CYP2C9 CYP2C19
13 (S)-limonene 6-monooxygenase activity GO:0018675 9.48 CYP2C9 CYP2C19
14 aromatase activity GO:0070330 9.46 CYP2E1 CYP2C9 CYP2C19 CYP1A2
15 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.35 CYP2E1 CYP2D6 CYP2C9 CYP2C19 CYP1A2
16 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.02 CYP2E1 CYP2D6 CYP2C9 CYP2C19 CYP1A2

Sources for Drug-Induced Hepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....